-->

Tech Seeker (TS)

Zymogenetics Inc
Profile last edited on: 6/19/2013

Recombinant thrombin. Protein-based therapeutics for the prevention or treatment of human diseases
TS Type
Small Corporation
Status
Acquired
Year Founded
1981
Last Involved Year
2003

Key People / Management

  Paul H Duesterhoft --

Location Information

1201 Eastlake Avenue East
Seattle, WA 98102
   (206) 442-6600
   www.zymogenetics.com

Public Profile

Formerly operating as an independent company after 12 years as a wholly owned subsidiary of Novo Nordisk A/S, in September 2010, ZymoGenetics Inc was acquired by Bristol-Myers Squibb. ZymoGenetics Inc. is focused on the discovery, development and commercialization of therapeutic proteins for the treatment of human disease. The Company has been longtime active in the area of therapeutic proteins having contributed to the discovery or development of many marketed recombinant protein products. These products include recombinant versions of proteins previously made from human or animal sources (Novolin (insulin) and GlucaGen (glucagon), marketed by Novo Nordisk) and novel proteins that come from its discoveries (NovoSeven (Factor VIIa), marketed by Novo Nordisk, as well as Regranex (platelet-derived growth factor), marketed by Ortho-McNeil Pharmaceuticals, Inc., a Johnson & Johnson company, and Cleactor (tPA analog), marketed by Eisai Co., Ltd).

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
375
Revenue
N/A
Public/Private
Publicly Traded
Stock Info
NASDAQ : ZGEN
Received SBIR $$
Yes

SBIR firms in the news

There are no news available.